Modus Therapeutics Holding AB — Investor Relations & Filings

Modus Therapeutics Holding AB is a clinical-stage biotechnology company focused on developing its proprietary polysaccharide, sevuparin. The drug candidate is being developed as a potential treatment for diseases with significant unmet medical needs, particularly those involving systemic inflammation. The company's primary focus is on the development of sevuparin for sepsis and septic shock. Additional indications under investigation include anemia related to chronic inflammation, such as in patients with chronic kidney disease, and other disorders characterized by severe inflammation and impaired blood flow.